Virginia Senator George Allen Tours Inoveon
For Immediate Release: April 15, 2005
Media Contact: George Fiedler, VP Marketing
405.271.9025 ext. 34777
george-fiedler@inoveon.com
Oklahoma City, April 15, 2005 - A leading congressional proponent of biotech and nanotechnology research toured Inoveon today as part of a visit to the Presbyterian Health Foundation Research Park. Virginia Senator George Allen, chairman and founder of the Congressional Nanotechnology Caucus, was accompanied on the tour by Oklahoma Senator Jim Inhofe who hosted a luncheon for Allen prior to the tour at the Presbyterian Health Foundation. Allen was governor of Virginia from 1994-1998 and is the son of the late Washington Redskins Head Coach George Allen.
Senator
George
Allen reviewd Inoveon's iScan retinal
imaging
technology with Dr. Lloyd Hildebrand
technology with Dr. Lloyd Hildebrand
"The type of research and work being done within these companies and the entire research parkway is extremely important," Allen said. "As a biotech and nanotech proponent, it's gratifying to witness the growth underway throughout these disciplines nationwide, and Oklahoma City and the Presbyterian Health Foundation Research Park certainly appear to be taking a back seat to no one. The facilities and entire complex is very impressive and I commend not only the biotech and nanotech company executives and staff, but the leadership of the Presbyterian Health Foundation for their understanding of the importance of this technology and their commitment to these scientists and research professionals."
"These outstanding Oklahoma biotech companies have each identified a unique niche in the biotech market and have chosen Oklahoma City as a strategic location to expand their business (distribution) to a national platform," said Presbyterian Health Foundation President Mike Anderson. "We are pleased the Research Park received the attention of such an influential national leader in the biotech and nanotech arena as Senator Allen."
About Inoveon:
Inoveon Corporation is the industry leader in the detection, staging and monitoring of diabetic retinopathy. Founded in 1997, Inoveon Corp. has successfully completed more than 35,000 clinical iScan retinal imaging studies. The service is delivered in partnership with large primary care and endocrinology clinics to improve the quality, convenience, economics, and medical outcomes of patients at risk for vision loss due to diabetes. Placing the service in the primary care environment helps to increase patient compliance with recommended annual dilated retinal evaluations and provides clinically rich information to improve patient care. For more information, visit the Web site at www.inoveon.com.